Payer

The study, backed by the digital therapeutics company, measured the change in clinical encounter frequency among opioid use disorder patients who were also prescribed buprenorphine.

Outcomes from the randomized controlled trial were presented today at a virtual conference. The company and its research partners say this study differs from others due to its size and length.

Dr. Liz Kwo reviews the opportunity for digital health apps for musculoskeletal health conditions and looks at challenges facing their wider adoption among providers.

Also: First Databank and RxCap collaborate on patient medication instruction and adherence app, Cohere Health is handling MSK prior authorizations for Humana.

Also: Livongo leverages Teladoc Health's connections for new business with Florida Blue; Amwell and Tyto Care reinforce partnership with "exclusive integrations."

More expertise will be necessary if the regulator is to keep up with the constant evolution of real-world evidence, privacy and other data-driven challenges, Dr. Hahn said.

Also: Study polls "digitally engaged physicians" on digital health's current strengths and weaknesses; Mira unveils an updated fertility monitor.

Efficient distribution, dissipating stigma and an emphasis on decentralized trials are all working in favor of digital treatments, according to a panel of digital therapeutics executives and industry stakeholders.

A new analysis of published RCTs did see significant benefits among short-term and single-focus app interventions, but noted that "relatively few high-quality studies have been conducted" in this area.

The 900-participant study uses learnings from Apple's Tueo Health acquisition and could inform the development of a digital biomarker for asthma.